arsenic trioxide has been researched along with Carcinoma, Basal Cell, Pigmented in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, C; Liu, J; Ma, YY; Wang, P | 1 |
| Ally, MS; Atwood, SX; Bailey-Healy, I; Beachy, PA; Chang, AL; Colevas, AD; Kim, J; Oro, A; Ransohoff, K; Rezaee, M; Sarin, K; Tang, JY | 1 |
| El Malki, K; Faber, J; Gerhold-Ay, A; Kron, B; Lehmann, N; Neu, MA; Paret, C; Pietsch, T; Russo, A; Seidmann, L; Sommer, C; Theruvath, J; Wagner, W; Wingerter, A | 1 |
| Aftab, BT; Beachy, PA; Borodovsky, A; Chen, B; Epstein, EH; Kim, D; Kim, J; King, EM; Lee, AH; Rezaee, M; Riggins, GJ; Rudin, CM; Tang, JY | 1 |
4 other study(ies) available for arsenic trioxide and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
Multiple Bowen's diseases and basal cell carcinomas in a patient with acute promyelocytic leukemia treated with arsenic trioxide: A case report and effective treatment with photodynamic therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Biopsy; Bowen's Disease; Carcinoma, Basal Cell; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Photochemotherapy; Skin Neoplasms; Treatment Outcome | 2018 |
Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Basal Cell; Drug Resistance, Neoplasm; Follow-Up Studies; Hedgehog Proteins; Humans; Itraconazole; Male; Middle Aged; Neoplasm Metastasis; Oxides; RNA, Messenger; Skin Neoplasms; Transcription Factors; Treatment Outcome; Zinc Finger Protein GLI1 | 2016 |
Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Axin Protein; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Carcinoma, Basal Cell; Cell Survival; Child; DNA Mutational Analysis; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Hedgehog Proteins; Humans; Inhibitory Concentration 50; Magnetic Resonance Imaging; Male; Mutation; Neoplasms, Neuroepithelial; Oxides; Patched-1 Receptor; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Proto-Oncogene Proteins; Repressor Proteins; Smoothened Receptor; Tumor Cells, Cultured; Up-Regulation; Wnt Signaling Pathway; Zinc Finger Protein GLI1 | 2016 |
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Topics: Anilides; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Basal Cell; Drug Resistance, Neoplasm; Hedgehog Proteins; Itraconazole; Medulloblastoma; Mice; Oxides; Pyridines; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor | 2013 |